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Cell therapy is a progressively growing field that is rapidly moving from preclinical model
development to clinical application. Outcomes obtained from clinical trials reveal the
therapeutic potential of stem cell-based therapy to deal with unmet medical treatment
needs for several disorders with no therapeutic options. Among adult stem cells,
mesenchymal stem cells (MSCs) are the leading cell type used in advanced therapies for
the treatment of autoimmune, inflammatory and vascular diseases. To date, the safety
and feasibility of autologous MSC-based therapy has been established; however, their
indiscriminate use has resulted in mixed outcomes in preclinical and clinical studies.
While MSCs derived from diverse tissues share common properties depending on the
type of clinical application, they markedly differ within clinical trials in terms of efficacy,
resulting in many unanswered questions regarding the application of MSCs. Additionally,
our experience in clinical trials related to critical limb ischemia pathology (CLI) shows that
the therapeutic efficacy of these cells in different animal models has only been partially
reproduced in humans through clinical trials. Therefore, it is crucial to develop new
research to identify pitfalls, to optimize procedures and to clarify the repair mechanisms
used by these cells, as well as to be able to offer a next generation of stem cell that
can be routinely used in a cost-effective and safe manner in stem cell-based therapies
targeting CLI.
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INTRODUCTION
Regenerative Medicine is a new paradigm that has driven
the revisiting of our understanding of biological and medical
processes and suggested new treatments. According to the
definition of the European Medicament Agency (EMA) and
the U.S. Food and Drug Administration (FDA), Advanced
Therapies include Cell and Gene Therapy and Tissue
Engineering. Advanced Therapies comprise a large group
of translational fields and targets in areas of unmet medical
needs. Briefly, the application of cells, either alone or engineered,
as a pharmacologically active substance seeks to restore
the functioning of damaged tissues or organs through the
protection of cellular integrity, the replacement of damaged
cells, and the promotion of trophic, anti-inflammatory, and
immunomodulatory effects, among others (Figure 1). This
new therapeutic avenue also carries unknown side effects that
must be deeply characterized to improve safety, feasibility,
and efficacy.
In this regard, mesenchymal stem cells (MSCs) are the cell
type commonly used in Regenerative Medicine due to their
unique biological properties, including ease of expansion and
culture. The predominant sources of stem cells are summarized
in Table 1, namely, cells derived from the fetus, and adult tissues
(1). Nine hundred forty-one studies using MSCs have been
reported to date (March 2019) and registered in the database
of privately and publicly funded clinical studies conducted
worldwide at “ClinicalTrials.gov.” MSCs are multipotent non-
hematopoietic progenitor cells with different degrees of stemness,
derived from the mesodermal germ layer and resident in
most tissues (Table 1). This type of cell (MSCs) can be easily
expanded in vitro because of their fibroblastic characteristics
and ability to adhere to plastic and to express specific surface
marker patterns (2, 3). The Mesenchymal and Tissue Stem Cell
Committee of the International Society for Cellular Therapy
(ISCT) first proposed that bone marrow plastic-adherent cells
generally described as “mesenchymal stem cells” should be
defined as “multipotent mesenchymal stromal cells,” while the
designation “mesenchymal stem cells” should be reticent for
a subset of these cells that show stem cell activity based on
clearly stated criteria (3). Since the acronym MSC may be
used to define both cell populations, the combined definition
“mesenchymal stem and/or stromal cells” is probably more
appropriate, especially when the “stemness” of the whole MSC
population has not been demonstrated (4), and it is now
widely accepted that MSCs represent a heterogeneous population
(5) but are considered a cellular medicament. Furthermore,
MSC survival, permanent engraftment and differentiation into
resident cells were initially thought to be necessary to obtain
the beneficial effects of these cells, and clinical experience
and several experiments have shown that one of the primary
functions of MSCs, most likely their key function, is to secrete
several bioactive molecules related to the environmental “niche”
in which these cells are located. Consequently, the secretome
transiently reproduces most of the effects of MSCs, and in
this sense, MSCs secrete a wide variety of pro-inflammatory
and anti-inflammatory cytokines, chemokines, growth factors,
and prostaglandins under resting and inflammatory conditions
(1, 6) (Figure 1).
These molecules are associated with immunomodulation
[indoleamine-2,3-dioxygenase (IDO), prostaglandin-E2 (PGE-
2), transforming growth factor beta (TGF-β), human leukocyte
antigen-G5 (HLA-G5), and hepatocyte growth factor (HGF)],
anti-apoptosis [vascular endothelial growth factor (VEGF),
granulocyte-macrophage colony-stimulating factor (GM-CSF),
TGF-β, stanniocalcin-1 (STC1), and insulin-like growth factor
1 (IGF-1)], angiogenesis [VEGF, monocyte chemoattractant
protein 1 (MCP-1), and IGF-1), local stem and progenitor
cell growth and differentiation support (SCF complex,
angiopoietin-1, and stromal cell-derived factor 1 (SDF-1)],
anti-fibrosis [HGF and basic fibroblast growth factor (bFGF)]
and chemoattraction [chemokine (C-C motif) ligand 2 and 4
(CCL2, CCL4), and C-X-C motif chemokine 12 (CXCL12 also
called SDF1)] (7). Immunomodulatory properties of MSCs
and their immunoprivileged condition make these cells good
candidates for use in several clinical trials related to chronic,
inflammatory and autoimmune diseases, and in reducing the
incidence and severity of graft-vs.-host disease (GVHD). MSCs
interact with cells of the innate or adaptive immune system
(T cells, B cells, NK cells, monocyte-derived dendritic cells,
and neutrophils). For a cell to be recognized by the immune
system, the expression of major histocompatibility complex
(MHC) and costimulatory molecules is necessary. MHC class
I and class II human leukocyte antigens (HLAs) are master
triggers of robust immunological rejection of grafts because
they present antigens to cytolytic T lymphocytes (CTL). The
interaction between MSCs and immune cells provides insights
into in vivo MSC-mediated induction of tolerance (1, 8). MSCs
display a low expression level of MHC-HLA class I, while they
are constitutively negative for HLA-class II; likewise, they do not
express costimulatory molecules such as CD80, CD86, CD40,
and CD40L (9). However, MSCs share the expression of surface
markers such as vascular cell adhesion protein 1 (VCAM-1),
intercellular adhesion molecule 2 (ICAM-2), and lymphocyte
function-associated antigen 3 (LFA-3 or CD58) with the thymic
epithelium, which are crucial for the interaction with T cells
(9, 10). Whereas, MSCs remain in a quiescent state showing
antiapoptotic properties and contributing to homeostasis, in an
inflammatory environment (presence of IFNγ, TNFα, IL-1α, and
IL-1β) they begin to exercise their immunomodulatory abilities,
inhibiting the proliferation of effector cells and their cytokine
production. Similarly, MSCs can block a variety of immune cell
functions (1, 11) (Figure 1).
In addition, there is a complex “cross-talk” interaction between
MSCs and endothelial cells. MSCs increase the proliferation and
migration of endothelial cells to promote the early events of
angiogenesis and to decrease the permeability of the endothelial
cell monolayer. In direct cocultures of MSCs and endothelial
cells, MSCs increase the persistence of preexisting blood vessels
in a dose-dependent manner (12). Additionally, beneficial
therapeutic effects of the use of conditioned media of MSCs have
been reported, which has even been shown to be therapeutically
superior to the cells themselves (13, 14) and to stimulate
the proliferation of local endothelial cells (15). Likewise, in
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FIGURE 1 | Effects of MSCs during therapeutic application. MSCs possess a broad range of paracrine effects, including anti-inflammatory, immunomodulatory,
trophic, antiapoptotic, and anti-fibrotic properties. Most of them are mediated by molecules released by MSCs, but also by direct cell-cell contacts. The paracrine
properties of MSCs have beneficial effects during cell therapy for regenerative medicine. However, the interaction between MSCs and the host may result in
adverse-side effects, including thrombotic events. B-cell, B lymphocyte; CXCL, C-X-C Motif Chemokine Ligand; DC, dendritic cell; G-CSF, granulocyte
colony-stimulating factor; HGF, hepatocyte growth factor; IL, interleukin; INFγ , interferon γ; MSC, mesenchymal stem cells; NK, natural killer cells; T-cell, T
lymphocyte; TGFα, transforming growth factor α; T-reg, regulatory T cell.
addition to direct “cell-cell” contact, there has been speculation
of a possible transfer of mitochondria or vesicular components
(secretome) that contain mRNA, microRNA and proteins (16).
Noteworthy, despite the anti-inflammatory, antiapoptotic, and
immunomodulatory characteristics of MSCs, and due to their
ability to migrate to sites of tissue injury and inflammation, many
concerns have been raised about their probable precancerous
activity (17). In this regard, the functions of MSCs can be
influenced by the existing microenvironment, making them
acquire supportive properties toward cancer cells (8, 18). To date,
no cancer has been diagnosed or has recurred in clinical trials
that would originate from experimentally given MSCs. However,
potential risks, related to the growth support and enhancement of
undetected or “resident” cancer cells, do exist, thus the potential
of tumorigenesis should be further explored and monitored
to detect the possibility of tumorigenicity related to MSCs
and likewise, the administration of MSCs-based therapies must
be thoroughly evaluated (8, 17, 18). However, although these
properties are generally attributed to all MSCs derived from
different tissues, preclinical and phase I/IIa safety, and feasibility
data also suggest that MSCs represent a potential therapeutic
option for the treatment of Critical Limb Ischemia (CLI).
Conversely, as mentioned above, evidence from different studies
has suggested that MSCs from diverse sources are not identical
and do not always achieve the same efficacy levels and desired
outcomes. Thus, MSC effects may be influenced by the constant
crosstalk between the graft and the host, which could affect
the MSC fate potential. For instance, autologous MSCs from
patients with inflammatory diseases (e.g., diabetes) may carry
phenotypic modifications, promoting undesirable effects on the
host when they come into contact with host signals (19). Here,
we will provide relevant information and alternatives to possibly
improve the use of MSC-based therapy to benefit type 2 diabetic
patients with CLI.
CRITICAL LIMB ISCHEMIA AND DIABETES
The term CLI is used for all patients with chronic ischemic rest
pain, ulcers, or gangrene in the limbs attributable to objectively
proven peripheral artery disease (PAD). PAD is associated
with several clinical conditions, e.g., diabetes, hypertension,
cardiovascular disease, hyperlipidemia, obesity, and stroke (20).
CLI is an advanced form of PAD, which is responsible for a
high rate of amputations and is a major cause of morbidity and
mortality worldwide. The incidence of CLI ranges from 500 to
1,000 new cases per million every year in Western Europe and
North America (21, 22), and this number is expected to grow
due to the aging population with a longer life expectancy and
progressive increase in the incidence and prevalence of diabetes.
It is estimated that more than 200 million people are living
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TABLE 1 | Human stem cell sources and subtypes.
Source Tissue Stem cells derived and acronyms Brief definitions
Fetal
Newborn
Abortus (fetal tissues)
Extra-embryonic tissues: Umbilical
cord
Wharton’s jelly
Amniotic membrane Amniotic fluid
Placenta
Fetal stem cells (FSCs)
Fetal structures like Wharton’s jelly-derived
mesenchymal stem cells (WJ-MSCs)
Amniotic membrane-derived mesenchymal stem
cells (Am-MSCs)
Yolk sac-derived mesenchymal stem cells
(YS-MSCs)
Umbilical cord-derived mesenchymal stem cells
(UC-MSCs)
Umbilical cord blood-derived mesenchymal stem
cells (UCB-MSCs)
Amniotic fluid-derived mesenchymal stem
cells (AF-MSCs)
Fetal stem cells are multipotent stem cells isolated from
two distinct sources, the proper fetus (fetal tissues), and
the supportive extra-embryonic tissues. These cells are
also known as “primordial germ cells” and are isolated
from tissues of 5- to 9-week fetuses obtained by
therapeutic abortion. The three most reliable sources to
date of abundant fetal stem cells are the placenta,
amniotic fluid, and umbilical cord blood.
Adult Bone marrow
Peripheral blood
Hematopoietic stem cells (HSCs)
Endothelial progenitor cells (EPCs)
Bone marrow-derived mononuclear cells (BM-MNCs)
Peripheral blood-derived mononuclear cells
(PB-MNCs)
Recombinant human granulocyte colony-stimulating
factor (G-CSF)
Hematopoietic stem cells are the stem cells that give rise
to other blood cells (hematopoiesis), a limited number of
hematopoietic stem cells are multipotent and capable of
extensive self-renewal.
Endothelial progenitor cells define a group of cell
population types with angiogenic activity. Endothelial
progenitor cells can be obtained from the bone
marrow-derived mononuclear cells fraction or from
peripheral blood, and they can also be found in umbilical
cord blood. Typically, endothelial progenitor cells are
selected by isolation and enrichment strategies focused
on the expression of surface markers CD34 and CD133.
Bone marrow stroma
Peripheral blood
Adipose tissues: Fat, liposuction
Others tissues: skin, gut, hair follicles,
skeletal muscle, cartilage, tendon,
synovium, perichondrium, cardiac
tissue, oral cavity, dental pulp,
salivary glands, etc.
Mesenchymal stem cells (MSCs)
Bone marrow- derived mesenchymal stem cells
(BM-MSCs)
Peripheral blood-derived mesenchymal stem cells
(PB-MSCs)
Adipose tissue-derived mesenchymal stem
cells (Ad-MSCs)
Mesenchymal stem cells are multipotent stem cells that
can differentiate into a variety of cell types, including
osteoblasts, chondrocytes, myocytes, and adipocytes.
Summary of fetal and adult stem cells subtypes. Modified from Hmadcha et al. (1).
with PAD worldwide (21), which is a common complication
in patients with type 2 diabetes (23). These two factors have
driven the development of a more severe degree of PAD. CLI
is not a specific disease per se; rather, it represents a syndrome
that may develop from distinct pathophysiological processes
(24). Although CLI is primarily a clinic-based diagnosis, it
should be confirmed objectively and early in the disease
process, e.g., through the ankle-brachial index (ABI), toe-brachial
index (TBI), first toe pressure (FTP), toe systolic pressure,
or transcutaneous partial pressure of oxygen (tcpO2). Further
computed tomography (CT), digital subtraction angiography
(DSA), Doppler echocardiography andmagnetic resonance (MR)
angiography are important non-invasive modalities for assessing
the severity of CLI (20, 25).
PAD is a condition that is characterized by atherosclerotic
occlusive disease of the lower extremities. While PAD is a major
risk factor for lower extremity amputation, it is also accompanied
by a high likelihood for symptomatic cardiovascular and
cerebrovascular disease. Although much is known regarding
PAD in the general population, the assessment and management
of PAD in people with diabetes is less clear and poses some special
issues. Presently, there are no established guidelines regarding
the care of patients with both diabetes and PAD (26), although
revascularization remains the most important therapeutic option
and the main objective of CLI treatment, either by open surgery
or endovascular modalities (27). Diabetic patients habitually
suffer from long-segment vascular obstruction, mainly of the
calf vessels (28) in type 2 diabetic patients, and the anatomic
extension and distribution of atherosclerotic occlusive disease
make these patients poor candidates for revascularization,
resulting in continued disease progression, amputation, and
death (28).
Thus, far, pharmacological treatment for these non-options
patients has not been shown to be effective in the CLI course
(29, 30). In fact, amputation is routinely recommended for these
patients as the only option, despite its obvious dysfunctional
involvement, along with the associated mortality and morbidity
(27, 29). Therefore, there is a need for new effective therapeutic
alternatives for a large number of patients with CLI (31).
In the diabetic patient, leg ischemia develops earlier and
with greater intensity than in other diseases (vasculitis, Buerger
disease). It is estimated that 15% of diabetic patients will
develop CLI, and in most cases, it will lead to amputation
(32). Of even greater importance, arterial lesions usually affect
the more distal vessels (29). This localization of lesions makes
revascularization difficult, either surgically or endovascularly.
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Furthermore, the clinical presentation of diabetic patients is also
different, as it entails a greater component of tissue loss and
gangrene, as well as fewer clinical manifestation of pain due to the
frequently associated diabetic neuropathy. Diabetic patients in
particular have fewer physiological mechanisms of angiogenesis
and reendothelization, and thus the course of the disease is
more severe and accelerated (26). The chronic hyperglycemia
present in diabetic patients results in vascular remodeling
altering neovascularization (30), with deficient and/or aberrant
angiogenesis (33). This phenomenon is partly due to the
associated oxidative stress, underlying endothelial dysfunction,
and lack of regeneration of the vascular endothelium (26,
34). In fact, neovasculogenesis is disrupted in diabetes and
metabolic syndrome due to hyperglycemia and increased
hemoglobin A1c (HbA1c), neuropathy, hypercholesterolemia,
oxidized low-density lipoproteins (Ox-LDL), reactive oxygen
species (ROS) or increased fatty acids (35–38). In healthy people,
homeostatic mechanisms, by which the vascular supply increases
to match metabolic demand, are activated (39). However, these
mechanisms are frequently disrupted in patients with CLI, and
the physiological response is not able to deliver the necessary
amount of blood flow and oxygen to the affected limb, causing
the arterioles of these patients to dilate to the maximum
and become insensitive to provasodilator stimuli (39). This
phenomenon, referred to as vasomotor paralysis, is considered
the result of chronic exposure to vasorelaxation factors in
patients with vascular diseases, which may explain the failure
of most vasodilator therapies to improve functional capacity in
individuals with PAD. Likewise, the blood vessels of patients with
CLI present a decrease in wall thickness, cross-sectional area, and
“wall-to-cell wall” ratio, among others.
The use of different types of stem cells in the treatment of CLI
is aimed at stimulating neovascularization in the area of severe
ischemia. The procedure consists of the administration of cells
in the ischemic tissues, either intravascularly or intramuscularly
(Table 2), to form new vascular structures and/or segregate a
number of angiogenic factors that regulate the process and favor
the recruitment of new cells (25, 40–51). The formation of
collateral blood vessels is promoted in an effort to improve blood
flow in ischemic tissue, as well as alleviate the symptoms of the
disease and, in most cases, prevent amputation of the affected
limb in patients who do not respond to conventional treatments.
The main objective of this process is principally regenerative,
restorative and anti-inflammatory (20, 25, 31). Despite the high
prevalence and incidence of CLI in diabetic patients, most studies
have excluded patients with diabetes or with high HbA1c (44, 47,
49, 50) (Table 2).
CLINICAL TRIALS FOR PAD, ISCHEMIA
AND CLI
The Route of Cell Administration
(Intraarterial vs. Intramuscular)
Since the publication of the Therapeutic Angiogenesis using
Cell Transplantation (TACT) study (52), more than 70 reported
clinical trials have been reported in patients with CLI. Only
25% of those studies included diabetic patients (25, 53). It is
known that several types of stem cells, derived from different
sources, have the propensity for vascular development, and could
potentially be useful in the management of CLI (Table 3). Some
of these cells have been used in preclinical models as well as
clinically to treat this condition. Among them, mononuclear
cells (MNCs) have been the most widely used (1, 8, 20), and
despite significant steps forward in defining their potential
for therapeutic purposes, further progress has been mired by
unresolved questions around their definition, and mechanism of
action and because of their heterogeneity (4, 54, 55).
We conducted a pilot prospective single-center study
(NCT00872326), phase I/IIa, that aimed to assess the safety
and efficacy of intraarterial administration of autologous bone
marrow-derived MNCs (BM-MNCs) in 20 diabetic patients
with CLI (25). As described by Isner and Asahara (56) and to
guarantee the homing of a great number of cells, BM-MNCs
were administered intraarterially into themost affected leg “target
limb” as close as possible to the ischemic area. One year after
BM-MNC infusion, there was a remarkable improvement in the
clinical status of most of the target limbs. In addition, the infusion
of BM-MNCs induced an unexpected benefit of an improvement
in the healing process, not only for ulcers but even for minor
amputations. Furthermore, early clinical benefits of cell infusion
consisted of patients having a widespread perception of less limb
pain, an increase in pain-free walking, and warmness in the target
limb. Unlike other studies, the cell dose was 10 times smaller than
the dose used by other groups. Moreover, and surprisingly, six
diabetic patients reduced their need to inject insulin, probably
due to a decrease in peripheral insulin resistance (25).
Similarly, the PROVASA study (Intraarterial Progenitor
Cell Transplantation of Bone Marrow Mononuclear Cells for
Induction of Neovascularization in Patients with Peripheral
Arterial Occlusive Disease Study), a multicenter, double-blind,
phase II trial (NCT00282646) with an estimated enrollment
of 40 patients with ischemic rest pain or non-healing ulcers
randomly assigned (1:1) to receive BM-MNC treatment or
placebo, demonstrated that in patients with CLI, intraarterial
administration of BM-MNCs does not increase ABI but promotes
ulcer healing and reduces rest pain. Furthermore, repeated
administration of functional BM-MNCs was required for
successful ulcer healing associated with improved limb salvage
(41). In this context, several studies have demonstrated the
feasibility of intraarterial delivery of BM-MNCs, their beneficial
effect on improving endothelial function (25, 57) and overall
improvements of ischemic pain and ulcer healing (25, 58).
However, the quality of evidence for efficacy is limited, as most
studies lacked a proper placebo or sham group because of the
invasive bone marrow harvesting procedure required to obtain
the cells (59–61).
Although intraarterial and intramuscular injection of
autologous BM-MNCs have shown similar results, and
combined intraarterial and intramuscular transplantation is
clinically feasible (62), to date, an overwhelming majority of
clinical studies targeting PAD have relied upon intramuscular
cell delivery (63). Intramuscular administration is easier and
less invasive, and it results in a transient placement of cells in
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TABLE 2 | Published studies using cell-based therapy to treat CLI.
Clinical trial ID
(www.clinicaltrials.gov)
Phase Cell type Route of
administration
Diabetic patients References
NCT00872326 I/II BM-MNCs Intraarterial Included (25)
NCT00371371 I/II BM-MNCs Intraarterial There is no data available (40)
NCT00282646 I/II BM-MNCs Intraarterial Included buerger disease (41)
NCT01480414 I/II BM-MNCs Intramuscular There is no data available (42)
NCT00221143 I/II PB-CD34+ Intramuscular There is no data available (43)
NCT00883870 I/II BM-MSCs Intramuscular Type 1 Diabetic patients were excluded (44)
NCT01595776 I/II Bone marrow derived- CD133+ Intramuscular There is no data available (45)
NCT01065337 II TRC Intraarterial
and Intramuscular
Included (46)
NCT00392509 I/II ALDHbr Cells Intramuscular Patients with HbA1c >8% were excluded (47)
NCT00523731 I NMPB-ACPs Intramuscular There is no data available (48)
NCT00468000 II Ixmyocel-T Intramuscular Patients with HbA1c >10% were excluded (49)
NCT00533104 I/II BM-MNC/PB-MNC Intramuscular Patients with HbA1c >7.5% were Excluded (50)
NCT00721006 II MESENDO Intramuscular There is no data available (51)
ALDHbr Cells, autologous bone marrow-derived Aldehyde Dehydrogenase-bright cells; Ixmyelocel-T, BM-MNCs (CD90+and CD45+/CD14+); Mesendo, combination of bone marrow-
derived MSCs and EPCs; NMPB-ACPs, non-mobilized peripheral blood angiogenic cell precursors; PB-CD34+, peripheral blood G-CSF-mobilized apheresis CD34+ cells; TRC, tissue
repair cells (expanded bone marrow cells enriched in CD90+ cells).
the ischemic tissue, whereas intraarterial infusion is designed to
directly inject cells into peri-ischemic areas, which are considered
to have sufficient oxygen and nutrients to support cellular
functions. Both delivery methods have obtained promising
results in the improvement of angiogenesis (64). Klepanec et al.
(65) compared the therapeutic effects of intramuscular and
intraarterial delivery of BM-MNCs in a randomized manner.
There were no differences among functional parameters in
patients undergoing intramuscular vs. intraarterial cell supply.
Preclinical (66) and clinical (67) data from our group substantiate
these remarks; nevertheless, our humble experience indicates
that the route of administration depends on the type and the dose
of cell to be administered. Deciphering how stem cells manage
the countless signals required for revascularization will improve
CLI recovery, Qadura et al. (31) proposed a combination delivery
of multiple cell types within supportive bioengineered matrices
as a new therapeutic strategy to target CLI.
Comparison of the Cell Type
Apart from the route of administration (intramuscular,
intraarterial, or combined), the most ideal cell type must
be identified, and a better understanding of the effective
subpopulation of stem cells is necessary as stem cells are a
heterogeneous population. Some clinical trials have directly
compared different cell populations (67–69) or used a
combination of angiogenic stem cells. Huang et al. (68)
evaluated the transplantation of peripheral blood-derived MNCs
(PB-MNCs) in the treatment of diabetic patients with CLI who
had received a subcutaneous injection of recombinant human
granulocyte colony-stimulating factor (G-CSF) to mobilize
progenitor cells, which resulted in clinical improvements
including reduced limb pain and ulcers, as well as no adverse
effects specifically due to cell transplantation and no lower
limb amputation in the transplanted patients. Tateishi-Yuyama
et al. (52) investigated the feasibility and safety of intramuscular
injection of MNCs and showed that in two groups of patients, the
first with unilateral ischemia infused intramuscularly with BM-
MNCs in the ischemic limb and saline in the less ischemic limb,
and the second with bilateral leg ischemia receiving random
intramuscular injections of BM-MNCs in one leg and PB-MNCs
in the other as a control, resulted in significant improvements
in patients treated with BM-MNCs compared with those treated
with PB-MNCs in terms of ABI and rest pain. Lu et al. (69)
compared the therapeutic effect of autologous intramuscular
administration of bone marrow-derived MSCs (BM-MSCs)
with BM-MNCs in 20 diabetic patients with CLI and foot ulcer.
The authors demonstrated that the healing rate of ulcers was
significantly higher in the group treated with BM-MSCs than
with BM-MNCs. Likewise, the authors concluded that BM-MSC
treatment was effective and better tolerated than BM-MNCs to
improve lower limb perfusion and to promote foot ulcer healing
in diabetic patients with CLI. Lasala et al. (51) evaluated the
efficacy and safety of autologous intramuscular administration
of a combination of MSCs and endothelial progenitor cells
(EPCs) in 26 patients with bilateral CLI. They found that
within this phase II clinical trial (NCT00721006), the enrolled
patients experienced an increase in perfusion in the treated limbs
compared with the control legs and improvement in pain-free
walking time and ABI after cell infusion. In this context, our
group proposed a phase I/II clinical trial (NCT02287974)
to study and compare the therapeutic effect of autologous
BM-MNCs, autologous BM-EPCs (CD34+/CD133+ cells)
and autologous adipose tissue-derived MSCs (Ad-MSCs) on
inflammatory and angiogenic cytokines, resistance to insulin and
a decrease in the need for insulin, as well as evaluating the safety,
viability and efficiency of the intraarterial infusion of these three
stem cells types in patients with type 2 diabetes with CLI. We
aimed to obtain related data on the source of suitable tissue,
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TABLE 3 | Registered clinical trials using cell-based therapy to treat CLI.
Clinical trial ID
(www.clinicaltrials.gov)
Phase Status Cell type Route of administration Patient condition
NCT00904501 III Completed BM-MNC Intramuscular Patients with HbA1c >7.5% were Excluded
NCT01408381 II Completed BM-MNCs Intraarterial Non-diabetic
NCT00987363 I/II Completed BM-MNCs Intraarterial Diabetic
NCT01867190 I/II Completed BM-MNCs Intramuscular There is no data available
NCT00595257 I/II Completed BM-MNCs There is no data available There is no data available
NCT00498069 – Completed BM-MNCs There is no data available There is no data available
NCT01245335 III Completed Bone marrow-derived
cells
There is no data available Patients with HbA1c >10% were excluded
NCT00616980 I/II Completed CD34+ Intramuscular There is no data available
NCT01584986 II Completed PB-ACPs Intramuscular There is no data available
NCT01351610 I/II Completed BM-MSCs Intravenous Patients with HbA1c >9% were excluded
NCT01484574 II Completed BM-MSCs Intramuscular Excluded diabetic patients
NCT01824069 I/II Completed Ad-MSCs Intramuscular There is no data available
NCT01257776 I/II Completed Ad-MSCs Intraarterial Diabetic
NCT01663376 I/II Completed Ad-MSCs Intramuscular There is no data available
NCT00919958 I Completed PLX-PAD Intramuscular Patients with HbA1c >9% were excluded
NCT00951210 I Completed PLX-PAD Intramuscular There is no data available
NCT01483898 III Completed Ixmyocel-T Intramuscular Patients with HbA1c >10% were excluded
NCT00955669 I Completed BM-MNCs and BM-MSCs Intramuscular Type 2 diabetic patients
NCT00518401 I Completed Mesendo Intramuscular There is no data available
NCT00913900 I Completed CD133+ Intramuscular There is no data available
NCT01019681 I Completed UCB-MNCs Intramuscular There is no data available
NCT02474121 – Available Bone marrow-derived
cells
Intramuscular Patients with HbA1c >10% were excluded
NCT01837264 I Active, not
recruiting
BM-MNCs There is no data available There is no data available
NCT00956332 I/II Active, not
recruiting
MultiGene
Angio
Intraarterial There is no data available
NCT01049919 – Ongoing, but
not recruiting
BM-MNCs Intramuscular Patients with HbA1c >10% were excluded
NCT01745744 I/II Ongoing, but
not recruiting
Ad-MSCs Intraarterial Non-diabetic
NCT01386216 I Recruiting BM-MNCs Intramuscular Patients with HbA1c >10% were excluded
NCT02099500 I/II Recruiting AD-MSCs liposuction Intramuscular Patients with HbA1c >10% were excluded
NCT02915796 I Recruiting G-CSF CD133+ Intramuscular Diabetic
NCT02140931 II Recruiting PB-ACPs Intramuscular There is no data available
NCT01833585 III Recruiting PB-MNCs G-CSF Intramuscular There is no data available
NCT02551679 II Recruiting PB-ACPs Intramuscular There is no data available
NCT02089828 – Recruiting CD34+ and PB-MNCs There is no data available There is no data available
NCT02234778 – Recruiting Ad-SVF cells Intramuscular There is no data available
NCT02805023 I/II Recruiting BGC101 Intramuscular There is no data available
NCT01456819 II Recruiting BM-MSCs and BM-MNCs Intramuscular There is no data available
NCT02454231 II/III Recruiting EPCs and BM-MNCs Intramuscular Patients with HbA1c >7.5% were excluded
NCT02864654 I/II Enrolling with
invitation
ADRC from lipoaspirate Intramuscular There is no data available
NCT02863926 I Not yet
recruiting
Bone marrow-derived
cells
Intramuscular There is no data available
NCT02538978 III Not yet
recruiting
BM-MNCs There is no data available There is no data available
NCT02501018 II Not yet
recruiting
CD34+ Intramuscular There is no data available
(Continued)
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TABLE 3 | Continued
Clinical trial ID
(www.clinicaltrials.gov)
Phase Status Cell type Route of administration Patient condition
NCT02477540 I Not yet
recruiting
BM-MSCs Intramuscular Type 1 diabetic patients are excluded
NCT01686139 I Not yet
recruiting
Allogeneic BM-MSCs Intramuscular Type 1 and 2 diabetic patients
NCT03042572 II/III Not yet
recruiting
Allogeneic BM-MSCs Intramuscular There is no data available
NCT03056742 II Not yet
recruiting
Allogeneic BM-MSCs Intramuscular Diabetic patients are excluded
NCT02993809 I Not yet
recruiting
BM-ECs and PRPE Intramuscular Patients with HbA1c >7% were excluded
NCT00488020 I Unknown BM-MNCs Intramuscular There is no data available
NCT00434616 II/III Unknown BM-MNCs There is no data available There is no data available
NCT01446055 I/II Unknown BM-MNCs There is no data available Patients with HbA1c >7% were excluded
NCT01903044 I/II Unknown BM-MNCs Intramuscular There is no data available
NCT00539266 II/III Unknown BM-MNCs Intramuscular Diabetic and non-diabetic
NCT00922389 I/II Unknown G-CSF and PB-MNCs Intramuscular YES (controlled)
NCT02336646 I Unknown Allogeneic BM-MSC Intramuscular Type 1 diabetic patients are excluded
NCT01216865 I/II Unknown UC-MSCs Intramuscular Type 2 diabetic patients
NCT01558908 I/II Unknown ERCs Intramuscular Patients with HbA1c >8.5% were excluded
NCT00145262 II Unknown BM-MSCs and BM-MNCs There is no data available Patients with HbA1c >6.5% were excluded
NCT02287974 I/II Unknown MNCs and CD133+ and
Ad-MSCs
Intraarterial There is no data available
NCT02145897 I/II Unknown SVF and Ad-MSCs Intramuscular and
Intravenous
Patients with HbA1c >7% were excluded
ADRCs, adipose-derived regenerative cells; Ad-SVF, adipose-derived stromal vascular fraction Cells; BGC101, mixture of cells enriched for EPCs and hematopoietic stem cells; BM-ECs,
bone marrow-derived endothelial cells; ERCs, endometrial regenerative cells; Ixmyelocel-T, BM-MNCs (CD90+and CD45+/CD14+); Mesendo, combination of bone marrow-derived
MSCs and EPCs; MultiGeneAngio, endothelial and smooth muscle cells; PB-ACPs, autologous angiogenic cell precursors; PLX-PAD, placenta-derived MSCs; PRPE, platelets rich
plasma; UC-MSCs, umbilical cord-derived MSCs.
the most appropriate cell type, optimal dose of cells, efficient
and low-cost protocols, among others, to be able to offer, in the
near future, a high-quality, economic, and effective therapy for
those patients without current therapeutic options. Despite the
extraordinary and unpaid efforts of the clinical research team
and promising preliminary results obtained during the first
year of follow-up showing beneficial but distinct effects of cell
type treatment, for unknown reasons the sponsor of this study
decided to prematurely terminate patient recruitment, and we
no longer have access to the clinical data.
The Use of MSCs
Regarding the use of MSCs as a cell-based therapy for CLI,
recent data suggest that the therapeutic effects of these cells
in ischemic pathologies are due to the secretion of angiogenic
molecules to bioactive levels and their ability to restore the
microenvironment of the damaged area (70). In preclinical
studies, the administration of autologous, allogeneic, and
xenogeneic MSCs derived from various sources such as bone
marrow, umbilical cord blood, fetal membrane and adipose tissue
have been shown to be beneficial in rat and mouse models
with lower limb ischemia (66). Subsequently, several phase I/IIa
clinical trials have been assayed in a limited number of patients
to demonstrate the safety and feasibility of MSCs obtained from
different sources (71–75). MSCs isolated from healthy donors
have shown uniform and consistent properties, whereas those
from patients affected by degenerative and/or inflammatory
disease differ in their biological and functional characteristics
(8, 19, 76). In this regard, other studies using MSCs isolated from
diabetic patients suggest that the hyperglycemic environment as
well as other metabolic disorders associated with diabetes affect
the cellular endogenous reserve and alter their proliferation,
differentiation and angiogenic capacity (19, 77–79). Likewise,
several groups have reported benefits of using autologous MSCs
as a cell-based therapy for a wide variety of diseases, such as
cardiovascular diseases (14, 31, 44, 51, 59, 61, 67, 71–75, 80–82),
diabetic nephropathy (83), and diverse brain injuries including
stroke, neural trauma, and heatstroke (84, 85).
In this regard, we have completed a phase I/IIa open
label, randomized, dose-scalable clinical trial with 30 diabetic
patients with CLI (NCT01257776) to test the safety and
feasibility of the administration of autologous Ad-MSCs. A
unique intraarterial cellular dose of 0.5 × 106 cells/kg (low
dose) or 1 × 106 cells/kg body weight (high dose) was
administered (86). Neovasculogenesis (assessed byMetaMorph R©
software quantification of DSA angiographies) (25) and clinical
improvement (evaluated by Rutherford-Becker classification,
University of Texas Diabetic Wound Scale, tcpO2, and ABI)
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were compared at baseline and at follow-up. After cell infusion
and after 1 year of follow-up, 40% of the diabetic patients with
CLI treated with the low, and 60% of the diabetic patients
with CLI treated with the high dose, respectively, experienced
an increase in vascularity in the ischemic areas (Figure 2 and
Table 4), which correlated positively with clinical benefits and
symptomatic improvement in the target limb. No patient suffered
any amputation (86).
Due to the combinatorial potential for inducing angiogenesis
and the immunomodulatory effects in situ of BM-MSCs, Gupta
et al. (44) reported the results of a randomized double-
blind randomized placebo controlled multicenter phase I/II
study examining the efficacy and safety of intramuscular
administration of allogeneic BM-MSCs in 20 patients with CLI
(NCT00883870). The administration procedure of BM-MSCs
at a dose of 2 × 106 cells/kg or placebo (PlasmaLyte A) was
found to be feasible and safe; however, few of the efficacy
parameters (such as ABI) showed significant improvements in
BM-MSC arm transplant patients. Although immunogenicity
may be unpredictable in cases where the administration of cells
is used for a different function in the recipient than in the
donor “heterologous use” or when injected into non-physiological
sites, no evidence of harm or adverse events was detected
FIGURE 2 | Follow-up of diabetic patients with CLI treated with Ad-MSCs.
Lower limb digital subtraction angiography (DSA) evaluation at 6- and
12-months follow-up after autologous adipose tissue-derived MSCs
(Ad-MSCs) administration showing substantial neovascularization at 12
months in target limb compared to baseline and to contralateral limb.
with allogeneic administration of MSCs obtained from different
source and prepared in different ways (81). This approach could
result in a safe, feasible option to avoid the time involved
in the process of isolation, expansion, and production of the
use of autologous cells. Regardless, it is necessary to continue
investigating this and other associated aspects to determine
which cell type is best and feasible for a specific pathology and
which type of patient health profile can benefit from this kind
of cell-based therapy. Thus, improvements in cell therapy will
benefit from a more precise characterization of cellular subsets
in the therapeutic product.
THE IMPAIRED PROPERTIES OF MSCs
COMPROMISE THEIR EFFICACY
Cell therapy is especially complex due to the nature of
the product. The cellular source, isolation and expansion
procedures, dose, site and procedure of administration define the
cellular medicament, even without a precise knowledge of the
mechanisms of action.
Immunogenicity
The administration of stem cells could interact with the
host immune response (for example, in a proinflammatory
environment) or have an immunomodulatory effect. Although
MSCs have been considered immune-privileged in this regard,
long-term exposure to the culture medium can make them more
immunogenic (MSCs are isolated and expanded in medium
that contains fetal bovine serum (FBS) and/or human platelet
concentrate), for example, by positively regulating the normal
set of histocompatibility molecules (82, 87). Thus, allogeneic
use of the cells may entail a greater risk of rejection by
the immune system. This rejection could lead to a loss of
function of the administered cells, and consequently, their
therapeutic activity could be compromised. Nevertheless, use of
immunosuppressants could limit these risks, but in turn could
cause adverse effects due to immunosuppressive medication.
Coagulation and Fibrinolytic Activity
MSCs have shown significant therapeutic potential due to their
fibrinolytic and antithrombogenic properties (88–92). To date,
several clinical trials have been conducted using autologous
MSCs for the treatment of diabetes and its complications, which
are presumably safer and more effective than allogenic cells.
However, the therapeutic effects of MSCs have been questioned
when they are derived from a diabetic milieu (19, 93–95).
MSCs isolated from healthy donors have shown uniform and
consistent properties, while those from patients, such as diabetic
patients, differ in their biological and functional characteristics
and can reduce the beneficial therapeutic effects of autologous
MSCs (19, 76, 79). In this regard, studies carried out by our
group and others using Ad-MSCs of diabetic patients suggest that
the hyperglycemic environment and other metabolic disorders
associated with diabetes affect the cellular endogenous reserve
and their proliferation, differentiation, and angiogenic capacity,
among other cellular characteristics (78, 79, 96, 97). Once infused
in the recipient, the cells come into direct contact with the
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TABLE 4 | Improvement of clinical outcomes after implant of Ad-MSCs: Evolution of Rutherford-Becker before (baseline) and 6 and 12 months of follow-up.
Groups (10 patients/group) Rutherford-Becker
grades
Baseline
cases (%)
6 months
cases (%)
12 months
cases (%)
Control 0 – – 1 (10%)
I – 2 (25%) 2 (20%)
II 8 (80%) 5 (62.5%) 6 (60%)
III 2 (20%) 1 (12.5%) 1 (10%)
Low dose 0 – 3 (30%) 4 (40%)*
I – 1 (10%) 1 (10%)
II 5 (50%) 2 (20%) 2 (20%)
III 5 (50%) 4 (40%) 3 (30%)
High dose 0 – 4 (40%) 6 (60%)*
I – 3 (30%) 3 (30%)
II 6 (60%) – –
III 4 (40%) 2 (20%) 1 (10%)
Rutherford-Becker grades: Grade 0 includes: Category 0, asymptomatic and Category 1, mild claudication; Grade I: Category 2, moderate claudication and Category 3, severe
claudication; Grade II: Category 4, ischemic rest pain; Grade III: Category 5, minor tissue loss and Category 6, major tissue loss, ulceration or gangrene.
*Percent in bold indicates an increase in vascularity in ischemic area of diabetic patients based on Rutherford-Becker improvement.
tissues, bloodstream and other patient cells, and the cell-recipient
interaction process still requires thorough investigation and
characterization. Physiologically, MSCs reside in the perivascular
compartment of almost every tissue (98, 99); however, one of the
hurdles to the sustained therapeutic success of these cells is early
cell loss, which is largely thought to be due to incompatibility
responses after systemic infusion of the cells, a reaction termed
the instant blood-mediated inflammatory reaction (IBMIR) (63,
82, 87, 97–100). This reaction suggests that the immune and
inflammatory system react to cells that normally are not in
contact with the blood circulation (Figure 3). Moreover, it has
been further shown that different MSC products display varying
levels of highly procoagulant tissue factor, a decrease in tissue
plasminogen activator (tPA) or an increase in plasminogen
activator inhibitor type 1 (PAI-1) and may adversely trigger
IBMIR or microthrombosis in the target tissue (19, 97).
MSCs are considered to be safe and even to promote
fibrinolysis (89, 91). Since type 2 diabetes is a systemic
inflammatory disease with a prothrombotic state, intraarterial
infusion of Ad-MSCs in diabetic patients was suggested and
approved by the Ethical Committee and the Regulatory Agency
as the appropriate treatment within a clinical trial conducted
by our group (NCT01257776), but unexpectedly during the
course of this clinical study, two patients developed distal
microthrombosis after intraarterial Ad-MSC infusion (19). These
two patients reported oppression at the infrapopliteal level and
vasomotor reaction of neurogenic origin in the distal third of
the target limb, accompanied by discreet pain, 10 h after the
cellular infusion. MR angiography demonstrated indemnity of
the arterial vessels of medium caliber. These two patients were
treated with antithrombotic therapy and discharged 72 h after the
symptoms disappeared (19).
Furthermore, Ad-MSCs induced an increase in expression
and release of PAI-1 and reduced levels of tPA. Likewise, the
quantification of D-dimer also decreased. These responses were
tested with MSCs of different origins exposed to different ex vivo
environment. Effects were more pronounced when Ad-MSCs
were from type 2 diabetic patients exposed to the sera of
same patients (Figure 4). Therefore, the efficacy of fibrinolysis
decreased favoring thrombosis, and these observations were
published (19) and a patent filed to identify these tentative
responses for cellular medicaments (US20160161504).
Altogether, new lines of research are being promoted that
focus on enhancing the therapeutic effects of stem cells by
regulating their biological characteristics (76, 96, 101–105). A
recent study conducted by our group has demonstrated the
beneficial effects of platelet-derived growth factor-BB (PDGF-
BB) in restoring the defective phenotype of Ad-MSCs derived
from type 2 diabetic patients with CLI (76). In particular, this
study showed that pretreatment with PDGF-BB could potentiate
proliferation, migration, and homing of defective MSCs, as
well as recover their impaired fibrinolytic ability (Figure 4).
Furthermore, we demonstrated that PDGF-BB utilized the
ERK-SMAD pathway to exert its beneficial effects. Therefore,
pretreatment with PDGF-BB represents a suitable strategy to
produce more effective MSCs for autologous therapies (76).
In this context, we postulated that either the use of allogenic
MSCs from healthy donors, rescue of the healthy phenotype by
pretreatment of autologous MSCs with PDGF (76), expression
of Akt (104) or angiotensin 1 (105), or the use of early-
passage autologous MSCs (106) will be an option to improve
the therapeutic effect of the cells. While we have clinical data
for the first scenario, the others have only been assessed in
preclinical studies; since a side effect is coagulation, pretreatment
with heparin (103) may overcome this problem.
CONSIDERATIONS FOR AN ADVANCED
THERAPY MEDICINAL PRODUCT
Safety, feasibility, and efficacy are mandatory to determine the
viability of a clinical application for the treatment of any disease.
With the exception of hematopoietic stem cell transplants, stem
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FIGURE 3 | Instant blood-mediated inflammatory reaction. (A) The direct contact between intravascularly infused MSC-based products and blood stream, promotes
inflammatory reaction known as instant blood-mediated inflammatory reaction (IBMIR). Adipose tissue-derived MSCs (AdMSCs) express tissue factor (TF/CD142) that
mediates the activation of blood coagulation cascade and complement system, leading to inflammation and thrombotic reaction. (B) Consequently, multiple
amplification reactions result in the activation of platelets and effector cells of immune system. (C) IBMIR is a multifaceted phenomenon that can compromise the
success of MSC-based cell therapy. CS, complement system; FXII, factor XII; HK, high molecular weight kininogen; PK, prekallikrein; TF, tissue factor.
cell therapies used for the treatment of any disease are considered
Advanced Therapies Medicinal Products (ATMP); therefore,
their development, approval and use must be in accordance with
specific standards established nationally and internationally for
such products. Thus, regulatory authorities warrant the safety of
the studies (8, 107).
Cell expansion and culture protocol are not yet standardized
(4). Currently, there is no protocol or universal definition
for stem cell culture and expansion Regulatory Agencies.
For example, the Spanish Agency of Medicines and Medical
Devices (AEMPS), the EMA and the FDA recommend a set of
standards to be followed for the production of an ATMP (EMA:
Regulation (EC) No 1394/2007 provides the overall framework
on ATMPs and FDA: designation described in Section 3033
of the twenty-first Century Cures Act; cell therapy medicinal
products are regulated in the Code of Federal Regulations
under Title 21 PART 1271, Human Cells, Tissues and Cellular,
and Tissue-Based Products). The different sources of origin, as
well as the different methodologies for obtaining tissue cells,
make it very difficult to compare research groups in search
of the fastest, most effective, economical, high-yielding, and
quality-required method.
Preclinical studies have shown that cell viability after infusion
is quite limited and that very few cells survive after infusion.
Although the in vivo follow-up in humans is ethically and
technically complicated, it is necessary to continue investigating
in this line to determine the intrinsic mechanisms of the
integration of the infused cells in the specific microenvironment.
Furthermore, the ATMP dose to obtain the desired effects
remains to be determined and defined. Our previous clinical
data (NCT01257776, NCT01745744, and NCT02287974) show
that an intraarterial dose of 1 × 106 cells/kg of body weight
is more effective that a dose of 0.5 × 106 cells/kg of body
weight (86). Experiments using mouse as animal models have
established a minimum dose of 1 × 106 cells/kg of body weight,
a quantity necessary to obtain a quantifiable but weak benefit.
The dose for ATMP treatment is determined by the patient’s
body weight and the biodistribution of cells and paracrine factors
secreted by the ATMP (MSCs) in the human recipient, and
most clinical trials usually use a similar ATMP dose (108, 109).
In most cases, the doses used for several clinical trials are
likely not sufficient to achieve the desired outcomes and a clear
therapeutic benefit. Therefore, collecting information regarding
ATMP doses obtained from different sources and the influence
of the host (patient recipient) medical conditions are important
for proposing future clinical trials and will undoubtedly assure
the safety and efficacy of ATMP-based therapies. Likewise, the
frequency of administration is currently not yet determined,
and the efficacy of ATMP-based therapy may be related to
a precise number of repeated applications (40, 42, 110), as
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FIGURE 4 | Implications of MSCs for thrombosis risk during cell therapy. Under physiological conditions, a delicate balance between the coagulation, and fibrinolysis
cascades are responsible for the effective dissolution of the clots within blood vessels. During cell therapy, transplanted MSCs may induce the expression of
pro-coagulant factors (e.g., TF and PAI-1) that disrupt the coagulation/fibrinolysis balance, increasing the formation of clots and leading to thrombotic events (19).
Approaches aimed to produce more safety MSC products are being investigated. For instance, the pretreatment of MSCs with PDGF results in cell products with
increased fibrinolytic activity, which may help to minimize thrombotic events during cell infusion (76). FVII, factor VII; FVIIa, factor VIIa; FX, factor X; FXa, factor Xa;
MMPs, metalloproteinases; PAI-1, plasminogen activator inhibitor type 1; PDGF, platelet derived growth factor; TIMP, tissue inhibitor of metalloproteinase; TF, tissue
factor; tPA, tissue plasminogen activator.
determined for a conventional medicinal product. Similarly, and
in addition to the doses, the duration of ATMP application
remains to be determined. Thus, ATMP-based therapy should
be as close as possible to conventional medicines and thus may
need to be adjusted accordingly. Finally, the method and route
of administration of ATMP remains inconclusive, representing
another variable to be considered in future clinical trials (97).
From our perspective, the most suitable ATMP (defined by
the cell type, culture media and standards, doses and route
of administration) for a particular disease or complication
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remains a challenge for Regenerative Medicine and requires
further investigation.
Therefore, the desired therapeutic effect depends on many
factors since the mechanism of action of an ATMP in tissue
regeneration is likely to be multifaceted; ATMP potency can
be determined by the ability of the injected cells to migrate,
survive, integrate, differentiate, and produce functional paracrine
mediator factor involved in “cell-cell interactions.” As mentioned
above, many diseases, including diabetes, affect the phenotypic
and therapeutic properties of an ATMP, and in the search
for safety and efficacy, the recipient tissue must respond
favorably to the administered ATMP, which would result in
the activation of endogenous regeneration mechanisms (111–
114). Understanding the integration of exogenous mechanisms
(injected ATMP) with the endogenous recipient (host) will play a
decisive role in the future clinical use of adult stem cells (8, 97).
NEW GENERATIONS OF ATMP
Advances in compliance under good manufacturing practice
(GMP) standards of more sophisticated cellular products are
now paving the way for new ATMP generations for use in
clinical trials.
The lack of therapeutic efficacy of the generation (Generation
1) of unmodified, naïve, and wild type MSCs rated in clinical
trials can be explained by the observation that, after their
systemic infusion (intravenous), these cells become trapped in
vascular filters (fundamentally liver and lung), with only a small
percentage reaching the target tissues. Therefore, it is essential
that we design strategies that favor their migration, nesting,
and localization in the inflammatory and/or infectious focus to
increase their effectiveness (Generation 2 MSCs) (111, 113).
Biodistribution and long-term follow-up of these cells in
animal models have shown that only a few cells persist after
long periods of transplantation. This phenomenon supports
the idea that most of the effects of MSCs are probably
based on a “hit and run effect.” To increase the implantation
of an ATMP in the injured tissue, Sackstein et al. (113),
developed a method to transiently modify the CD44 antigen
present in the MSC cell membrane by enzymatic fucosylation,
converting this molecule into HCELL glycoform and thus
favoring the migration of MSCs to the inflamed tissues (111,
FIGURE 5 | NOMA-Project considerations. (A) Intramuscular infusion of stem cells directly into the muscles. Once the targeted muscular injection points of MSCs are
selected (upper panel), repeated administrations of the therapeutic stem cells are directly, easily, and less invasively infused into the lower part of the limb (lower panel).
(B) Flowchart of the phases (enrollment, intervention allocation, follow-up, and data analysis) of NOMA clinical trial.
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115, 116). This method, called glycosyltransferase-programmed
stereosubstitution (GPS) to custom modify cell surface glycans
without affecting cell viability, has been optimized for its clinical
application using an alpha-1,3-fucosyltransferase preparation
and enzymatic conditions specifically designed to treat live cells
and formulated to preserve the cell viability and phenotype. It
has been found that this modification not only increases the
adhesion of the MSCs to the endothelium but also enhances
their transmigration through it by activating integrin α4β1 (VLA-
4) in the absence of chemokine stimulation. Therefore, this
modification by fucosylation could improve the efficacy of the
treatment with MSCs by increasing their migratory capacity to
the inflamed tissues after systemic administration. More detailed
knowledge of the mechanisms of biodistribution, migration and
specific interaction ofMSCs at the damaged loci may be beneficial
to design new ATMPwith increased safety and efficacy (111), and
in this regard, our group has collaborated in a patent to classify
these tentative responses for stem cells (WO2017032612).
In this context, and as another approach, a new generation
of MSCs can be engineered by increasing both cell migration
and cell potency (Generation 3 MSCs). Targeting the CXCL12
and C-X-C chemokine receptor type 4 (CXCR-4) may improve
the cell migration capacity of transplanted MSCs, and CXCL12
is also highly expressed in injured tissues and contributes to
the recruitment of CXR4-positive cells. As a small proportion
of MSCs express CXCR4 in culture, their capacity to migrate,
and to respond to homing signals in damaged tissue may
be reduced. Therefore, targeting CXCR4 may improve the
migratory and therapeutic effects of MSCs (117). Within this
context, we propose using MSCs modified to overexpress
CXR4 and IL10 and/or IL7 (Generation 3 MSCs). Expression
of the CXCR4 receptor will increase the migration of MSCs
toward the inflammatory focus, while coexpression of the
anti-inflammatory cytokine interleukin 10 (IL-10) and/or the
anti-infectious cytokine interleukin 7 (IL-7) will increase the
anti-inflammatory effect (IL-10) and even the anti-infective
effect (IL-7).
Furthermore, we propose that the extensive use of FBS in
MSC expansion media represents a clear limitation for the
introduction of an ATMP at the clinical level. Currently, cell
expansion is carried out in culturemedia supplemented with FBS.
Serum use must be of a clinical grade (free of animal pathogens).
Together with the growing demand for MSCs, this feature has
led to a series of technical and ethical conditions for production
(use of a large number of bovine fetuses) and geographic regions
(zones free of prion diseases) with an associated impact on
price (118–124). The substitution of FBS with human serum
and platelet lysate also represents a technical limitation that
is mainly related to the supply of human material and the
absence of uniformity of the lots. Altogether, these considerations
have enforced the development of robust processes of MSC
production in chemically defined culture media free of animal
and human components. These media are supplemented with
recombinant proteins (albumin, insulin, TFGβ and bFGF), iron,
selenium, and an antioxidant system (2-mercaptoethanol) (119,
122). The use of serum-free and xeno-free media minimizes
the possible risks of contamination and adverse effects with
respect to clinical application. Although several serum-free
media have been described in the literature, they are chemically
defined and contain known molecular components and are
commercially available for cell manufacturing. We propose using
our patented xeno-free and human component-free medium
(WO2017021535) to expand modified MSCs.
COST OF THE PROCESS
After the introduction of CAR-T cell therapies with an actual
cost of ∼300,000 to 400,000 e (125) or the prices charged by
PROCHYMAL (an allogeneic bone marrow-derived allogeneic
MSC treatment for graft vs. host disease) or Provenge (an
autologous cell therapy of dendritic cells from metastatic forms
of prostate cancer), with prices between $100,000 and $200,000
US, it seems absolutely necessary to analyze the cost-effectiveness
of a potential treatment to facilitate the universal coverage of
healthcare. A recent survey from the International Society for
Stem Cell Therapy estimates costs for a dose between 10,000 and
25,000e (126), with additional costs from hospitalization and the
endovascular department, among others, resulting in a total cost
of 30,000 to 40,000 e for a single dose. This cost may be assumed
for rare diseases with a low prevalence, but it seems quite difficult
to extend this treatment to a highly prevalent medical condition.
The only way to reduce the cost is the mass production of
allogeneic doses and facilitation of administration. Intramuscular
administration of allogeneic MSCs will reduce the total cost
and may be as effective as the intraarterial route. The NOMA
(No More Amputations) Project is aimed to address these
points (Figure 5A). Previous cell therapy clinical trials conducted
by our group have used autologous cells (BM-MNCs, BM-
EPCs, and Ad-MSCs) injected intraarterially (NCT00872326,
NCT01257776, NCT01745744, and NCT02287974). Given the
reported adverse events, such as microthrombosis (19), clot
formation (96), or IBMIR (82, 87, 97), the high cost of the
treatment of complications and our preliminary data suggesting
that allogeneic MSCs administered intramuscularly may be as
safe and effective as intraarterial autologous MSCs, we decided to
promote the NOMA Project. A description of the Project (aims,
endpoint, inclusion, and exclusion criteria, follow-up, indicators
and monitorization) will be published elsewhere (Figure 5B).
The development of a safe and new generation ofMSCs expanded
under GMP conditions with media free of FBS and human
platelet lysate (HPL) is currently under development.
We have now treated a huge number of patients with cell
therapies, and the insights that we are gaining concerning
the optimization of the next-generation of cell-based therapies
should not be underestimated.We propose a combination among
the following factors:
- A new source of healthy allogeneic donors (NOMA Project)
- A cost-effective mass production under GMP conditions (to
be developed)
- A safe, friendly and less costly procedure for administration,
for example, via the intramuscular route (NOMA Project)
- A new xeno-free culture medium (to be developed)
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INSTITUTIONAL REVIEW BOARD AND
REGULATORY COMPLIANCE
Clinical Trials
The clinical trials developed and conducted by our group
were promoted by “Fundación Progreso y Salud” under a non-
commercial investigator-driven grant, were approved by the
local institutional review board (IRB), the regional Andalusian
Ethics Committee, and registered in the Clinical Trials Database
(www.clinicaltrials.gov), except for NOMA Clinical Trial (No-
More-Amputations (NOMA); PIC18/00010; Clinical Trials of
Independent Advanced Therapies).
Regulatory and ATMP Manufacturing
For the clinical trials mentioned above, the donors’ source
for ATMP was appropriately screened and tested for human
pathogens. The therapeutic protocols were approved by the
hospital ethics committee in accordance with Spanish law.
All patients signed a detailed informed consent form before
intervention and provided their consent for publication of the
study results. These studies were conducted in accordance
with the ethical standards of the Helsinki Declaration
(1975). The clinical studies (NCT01257776, NCT01745744,
and NCT02287974) fulfill GMP standards for application
in a clinical setting. All procedures were performed in
a CABIMER-GMP core facility, a certified clean room
(Certificate No: ES/101I/18; inspected in accordance with
Directive 2001/20/EC) that complies with the principles and
guidelines of Good Manufacturing Practice laid down in
Directive 2003/94/EC.
CONCLUDING REMARKS
Considering all the previously findings and despite promising
results, the ATMP-based therapy applied to CLI has led
to important questions regarding safety and efficacy that
can be transferred to its application for other pathologies.
Although MSCs display a series of properties (factor release,
immunomodulation, inflammatory capacity, among others),
we presently do not know how many clinical trials are
necessary before a specific, safe and effective cell-based
therapy can be successfully achieved to offer patients
with no other therapeutic alternatives. Improvements in
personalized cell production in a cost-effective, safe and
effective manner, a correct diagnosis, clinical prognosis
and well-defined patient profile, and the correct route of
administration will undoubtedly improve this advanced cellular
medicine therapy.
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